- Home
- INDP vs ACXP Comparison
INDP vs ACXP Comparison
Compare INDP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- ACXP
- Stock Information
- Founded
- INDP 2000
- ACXP 2017
- Country
- INDP United States
- ACXP United States
- Employees
- INDP N/A
- ACXP N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- ACXP Health Care
- Exchange
- INDP Nasdaq
- ACXP Nasdaq
- Market Cap
- INDP 6.0M
- ACXP 6.8M
- IPO Year
- INDP N/A
- ACXP 2021
- Fundamental
- Price
- INDP $3.62
- ACXP $4.24
- Analyst Decision
- INDP Strong Buy
- ACXP Strong Buy
- Analyst Count
- INDP 2
- ACXP 3
- Target Price
- INDP $238.00
- ACXP $143.67
- AVG Volume (30 Days)
- INDP 1.4M
- ACXP 89.0K
- Earning Date
- INDP 11-11-2025
- ACXP 11-12-2025
- Dividend Yield
- INDP N/A
- ACXP N/A
- EPS Growth
- INDP N/A
- ACXP N/A
- EPS
- INDP N/A
- ACXP N/A
- Revenue
- INDP N/A
- ACXP N/A
- Revenue This Year
- INDP N/A
- ACXP N/A
- Revenue Next Year
- INDP N/A
- ACXP N/A
- P/E Ratio
- INDP N/A
- ACXP N/A
- Revenue Growth
- INDP N/A
- ACXP N/A
- 52 Week Low
- INDP $2.22
- ACXP $3.80
- 52 Week High
- INDP $58.24
- ACXP $43.20
- Technical
- Relative Strength Index (RSI)
- INDP 45.47
- ACXP 51.39
- Support Level
- INDP $2.86
- ACXP $3.97
- Resistance Level
- INDP $4.50
- ACXP $4.85
- Average True Range (ATR)
- INDP 0.99
- ACXP 0.35
- MACD
- INDP 0.25
- ACXP -0.02
- Stochastic Oscillator
- INDP 19.01
- ACXP 23.45
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.